TP53 and lung carcinoma: Considering that p53 has been found to be mutated in more than 50% of human cancers and is known to be responsible for chemoresistancy in cancer patients [18], the biological activities of P. cocos and its constituents need to be further evaluated in human lung cancer cells with various p53 statuses so that the therapeutic potential of these components against lung cancer can be verified and broadened.